ID: MRFR/Pharma/1557-HCR | February 2021 | Region: Global | 80 pages
Market Synopsis of Monoclonal antibody therapy Market:
Monoclonal antibodies are laboratory-produced antibodies structured to be the substitute of natural antibodies which can enhance or mimic the immune system's attack on harmful cells. Monoclonal antibody therapy is a type of immunotherapy which requires monoclonal antibodies to bind specifically to certain type of cells and proteins which stimulates the immune system to attack those cells. Currently, it is possible to produce monoclonal antibodies specific to any extracellular target and research is being carried out to amplify the application scope of the monoclonal antibodies in different areas of medical science. Globally, the market for monoclonal antibody therapy is growing rapidly and it is expected to grow at the rate of about XX% from 2016 to 2022.
Study objectives of Monoclonal Antibody Therapy Market:
Monoclonal antibody therapy Market, by Region
Regional Analysis of Monoclonal Antibody Therapy Market
Globally North America is the largest market for monoclonal antibody therapy. Europe is the second-largest market. Furthermore Asia pacific market is expected to be the fastest growing market for monoclonal antibody therapy.
Key Players for Monoclonal Antibody Therapy Market
Some of the key players in this market are: AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol – Myers Squibb Company, F. Hoffmann-La Roche Ltd., GenScript, GlaxoSmithKline Plc., Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sigma-Aldrich Co. LLC, and others.
The report for Monoclonal Antibody Therapy Market of Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insights of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information and strategies of the top key players in the industry. The report also gives a broad study of the different market segments and regions.
|Market Size||2027: Significant Value|
|CAGR||2020-2027: Substantial CAGR|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||source, application and end users|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol – Myers Squibb Company, F. Hoffmann-La Roche Ltd., GenScript, GlaxoSmithKline Plc., Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Sigma-Aldrich Co.|
|Key Market Opportunities||Joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments|
|Key Market Drivers||technological advancement, macro economical and governing factors|
Frequently Asked Questions (FAQ) :
The global monoclonal antibody therapy market is projected grow at 10.5% CAGR during the assessment period (2016-2022).
The valuation of the global monoclonal antibody therapy market is estimated to increase to USD 140 BN by the end of 2022.
The Recombinant segment holds the largest share in the global monoclonal antibody therapy market.
North America holds the largest share in the global monoclonal antibody therapy market, followed by Europe and the Asia Pacific, respectively.
Amgen Inc., AbbVie Inc., Bayer AG, Bristol–Myers Squibb Company, Biogen Inc., GenScript, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., Merck KGaA, Johnson & Johnson, Novartis AG, Sanofi, Pfizer Inc., and Sigma-Aldrich Co. LLC, are some of the major players operating in the monoclonal antibody therapy market.